Genfit sinks 31%, but CEO defends liver drug results
0
The CEO of biotech company Genfit told CNBC that the markets are overreacting to the results of its NASH study.
The CEO of biotech company Genfit told CNBC that the markets are overreacting to the results of its NASH study.